EGFR and head and neck squamous cell carcinoma: Preliminary evidence of clinical activity included two confirmed partial responses (PRs) in SCCHN patients (18) who had entered the duligotuzumab phase Ia study after progressing on prior therapy, one having relapsed after multiple prior treatment regimens including an EGFR inhibitor.